My name is Taka. I am the owner of TAKA, Japanese restaurant in Buckhead, Atlanta, USA.
I opened this small place in 2002.
Restaurant business is drama without script. It is fun and stress. But the word of "Thank you. It was delicious." is everything. It is encouragement, reward, vitamin for tomorrow. I write my everyday's drama here.
Thanks for all.
Wednesday, September 19, 2012
Taka Update September 19, 2012
Taka Update September 19, 2012
delivery and more
Tuna situation is same as last week. I asked our supplier
for this issue. The reason we cannot get good tuna is very simple. It is hurricane.
Many tropical storms are available around central Atlantic Ocean. Fishermen don’t
want to die for it. That’s why. I can tell it. We could get good tuna before
Issac came to Gulf of Mexico. After Issac, everything had changed. We could net
get good tuna.
Other fish are fine. Uni is available and quality is
Control and Golf
I lost my weight very
at moment. That was Monday morning after 2 days of Japan Fest event. It was
168.4 lbs. I really worked hard last week. 4 hours sleep on Friday night, 5
hours sleep on Saturday night. And I lost 3 lbs. But it came back to 170.2 lbs
this morning. I feel fine with this weight.
No play golf last
weekend, and I will not play this Sunday. I met Dustin Johnson yesterday. He
After No more Highchair
People still bring their
babies or kinds. They bring their tools and make comfortable their kids. The
only a couple came and left because of no highchairs.
So, it’s same and does
not matter. They don’t like babysitting and bring their families.
Babies cry and scream
before 7pm. That’s why we do happy our and reduce drink prices.
Safety Monitoring of Drugs Receiving Pediatric Marketing
The Food and Drug
Administration (FDA) Modernization Act provided for an additional 6-month
period of marketing exclusivity to companies that perform pediatric drug trials
in response to an FDA-issued written request. Because many safety concerns
cannot be detected until after the introduction of a product to a larger and
more diverse market, the Best Pharmaceuticals for Children Act required the FDA
to report to the Pediatric Advisory Committee (PAC) on adverse events occurring
during the 1-year period after granting pediatric exclusivity. We sought to
describe the PAC’s recommendations made in response to safety reviews informed
by data from the FDA’s Adverse Event Reporting System in 67 drugs granted
PAC meetings and data
presented by the FDA for all drugs were reviewed from June 2003 through April
2007. We divided the drugs into 2 groups: those that were returned to routine
adverse event monitoring and those that had specific PAC recommendations.
Forty-four (65.7%) drugs
were returned to routine monitoring for adverse events. The PAC, sometimes
working with other advisory committees, recommended label changes for 12
(17.9%) drugs, continued monitoring for 10 (14.9%), production of MedGuides for
9 (13.4%), and an update on label changes resulting from discussions with the
sponsor for 1 (1.5%) drug. Some drugs had more than 1 action. Several of the
adverse events revealed during this process were rare and life-threatening.
during the early post-marketing period is crucial to detect rare, serious, or
pediatric-specific adverse events. Fortunately, the majority of drugs given
exclusivity had no adverse events of a frequency or severity that prevented a
return to routine adverse event monitoring.